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ess: violaine.giraud@ivSummary Qvars Autohalers efficacy on asthma control, assessed with E. Juniper
asthma control questionnaire (ACQ), was compared with fluticasone and budesonide.
An open randomized study, stratified (2:1) on the intake of long-acting b2-mimetics
(LAb2), was performed in patients with moderate to severe poorly controlled asthma
(defined by at least one nocturnal discomfort in the last 5 days or a mean of 2 puffs
of short-acting b2-mimetics in the last 7 days or exercise dyspnea) despite treatment
with beclomethasone p1000 mg/day (or equivalent). 460 patients received Qvar
Autohaler 800 mg/day (n ¼ 149), fluticasone Diskus 1000 mg/day (n ¼ 149) or
budesonide Turbuhaler 1600mg/day (n ¼ 162) during 12 weeks. Asthma control
improved in all groups, with no difference between groups. For patients treated with
LAb2 (n ¼ 286) a significantly greater improvement of the ACQ score was obtained
with Qvar Autohaler versus fluticasone (1.071.0 vs. 0.670.9; P ¼ 0:019), but not
versus budesonide (0.970.9). Pulmonary function test improvements were similar in
the 3 groups. The significant improvement in asthma control in patients receiving
LAb2 suggests potential advantages for extrafine aerosols as part of anti-
inflammatory treatment optimization.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Beclomethasone dipropionate (BDP) is a synthetic
halogenated corticosteroid which has been avail-
able since 1972 for inhalation asthma therapy.
Following the Montreal Protocol1 that has led
pharmaceutical companies to develop new propel-
lants for metered-dose inhalers (MDIs) BDP was
reformulated using the new HFA-134a propellant
system as Qvars aerosol or Qvars Autohalers,
hereafter referred to as Qvar Autohaler.
Due to reformulation, Qvar Autohaler delivers an
extra fine aerosol with a mass median aerodynamic
diameter (MMAD) of 1.26 mm2 and improves the fine
respirable mass with a greater proportion of
particles with a diameter less than 4.7 mm (approxi-
mately 60%) compared to conventional CFC-BDP
press-and-breathe MDI (approximately 30%).3 Radi-
olabel deposition studies in healthy volunteers
showed that Qvar press-and-breathe MDI deposited
55–60% of the ex-actuator dose in the airways and
only 29–30% in the oropharynx.2 A similar study in
16 patients with asthma showed that Qvar Auto-
haler delivered 56% radiolabeled BDP to the lung
and 33% to the oropharynx.4 In comparison, con-
ventional press-and-breathe MDIs deliver 5–30%
drug to the lungs and 70–95% to the oropharynx.2
Therefore by targeting lung deposition more
efficiently, there is potential for better efficacy
from Qvar Autohaler. Data from two safety and
efficacy studies in adults support the view that
Qvar administered at around half the dose will
produce the same asthma control and safety profile
as formerly marketed CFC BDP.5,6 Moreover, the
constraint linked to the mandatory replacement of
chlorofluorocarbons gave the opportunity to im-
prove drug delivery of inhaled corticosteroids,
especially to the small airways3 whose impairment
has been recently underlined. Indeed, pathologic
studies have given evidence that the inflammatory
process extends beyond the central airways, to
the peripheral airways and lung parenchyma.7–10
Moreover, small airways impairment is associated
with asthma exacerbations and poor asthma
control.11–13
According to guidelines, asthma control is the
main objective of asthma treatment and its
evaluation is more complete than traditional end
points like isolated clinical or functional para-
meters.14 It is based on symptoms, beta agonist use
and functional test.15 It can be assessed indepen-
dent of severity level with the quantitative asthma
control questionnaire (ACQ), developed and vali-
dated as by E. Juniper.15,16
The present study was conducted in patients with
moderate to severe asthma to compare theefficacy, in terms of improvement of asthma
control, of Qvar Autohaler 800 mg/day with the
other two main inhaled corticosteroids adminis-
tered at equipotent dosages and with breath-
actuated devices (fluticasone Diskuss 1000 mg/day
and budesonide Turbuhalers 1600 mg/day), in adult
patients.Patients and methods
Patients
The study included patients of either sex, aged
18–60 years, presenting with moderate to severe
asthma, not controlled with a regimen of inhaled
corticosteroids: fluticasone p 500 mg/day or bude-
sonide p 800 mg/day, corresponding to p 1000 mg/
day CFC-beclomethasone with or without long-
acting b2-mimetics (LAb2). Poor control was de-
fined by at least one nocturnal discomfort during
the last 5 days and/or asthma requiring on average
2 puffs per day of short-acting b2 agonists (SAb2)
p.r.n. during the last 7 days and/or asthma
responsible for exercise dyspnea.
Non-inclusion criteria were: chronic obstructive
pulmonary disease, upper or lower airway infection
in the preceding month, exacerbation of asthma
symptoms requiring a visit to an emergency unit,
oral or injectable corticoids with immediate or
prolonged action, ongoing or within 30 days before
inclusion, and treatment with nasal corticosteroids
if daily dosage greater than 400 mg/day equivalent
BDP or variable dosage.
The study was conducted by 69 French pneumol-
ogists. The protocol was reviewed by the indepen-
dent Ethics Committees of Lyon-A, and informed
written consent of the patients was obtained
before inclusion. This study was conducted and
monitored in compliance with the French regula-
tory guidelines (Loi Huriet), the European Medi-
cines Evaluation Agency (EMEA) Notice to Marketing
Holders Pharmacovigilance Guidelines, EMEA
Guidelines for post marketing survey studies for
Metered Dose Inhalers with New Propellants and
the ethical principles enunciated in the revised
Declaration of Helsinki (Somerset West, Republic of
South Africa, 1996).
Study design
This was an open label, Phase IV, randomized,
parallel-group study, with stratification (2:1) on the
concomitant treatment (yes/no) with LAb2, that
should remain unchanged throughout the study.
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process, patients were to receive during 12 weeks
either Qvar Autohaler 800 mg/day, fluticasone Dis-
kuss 1000 mg/day or budesonide Turbuhalers
1600 mg/day.
The score for the validated French version of the
Juniper asthma control questionnaire was calcu-
lated at each of the four visits scheduled at
4-weekly intervals (75 days). This questionnaire
includes seven items, six of which evaluate the
diurnal and nocturnal symptoms and short-acting
b-agonist use during the last 7 days. The last item is
the forced expiratory volume in 1 s second (FEV1)
expressed as the percentage predicted value.
The primary outcome parameter was the evolu-
tion of the score between baseline and the last
assessment. Pulmonary function tests were to be
performed at each visit in the same conditions for
each patient. The spirometric measurements as-
sessed included: FEV1, vital capacity (VC), FEV1VC,
FEF25–75. Plethysmography measurements in-
cluded: residual volume (RV), functional residual
capacity (FRC) and total lung capacity (TLC). The
European Respiratory Society predicted values
were used for calculations.
Compliance was assessed at the end of the study
by weighing the bottles of Qvar Autohaler and
budesonide (to calculate the number of remaining
doses) and counting the remaining doses of flutica-
sone. The percentage of compliance was calculated
as (number of actual intakes/number of theoretic
intakes) 100.
Local safety was assessed at each visit by
recording the occurrence of items regarding oro-
pharyngeal tolerance: dysphonia, clinical signs of
candidiasis, hoarse voice, and cough within 15min
after inhalation or other local effects. General
adverse events were also collected, with recording
of dates of onset and resolution, intensity (sub-
jective assessment of mild, moderate or severe),
seriousness and causal relationship of study treat-
ment in the investigator’s opinion.Statistical considerations
This study was designed to show the superiority of
Qvar Autohaler versus fluticasone Diskus and
budesonide Turbuhaler. A decrease of 0.5 point on
Juniper score being considered clinically significant
and previous results showing an overall change of
0.73 point,17 the expected mean decreases were
set to be 0.9, 0.65, 0.65 points for Qvar, fluticasone
and budesonide, respectively. To show a significant
difference either between Qvar versus fluticasone
or Qvar versus budesonide, 480 patients were to beincluded (power: 80%, SD: 0.65; drop-outs: 20%)
with an alpha equal to 2.5% (2 comparisons) for a 2-
tail test.
When more than 50% patients were included in
the study, it appeared that the standard deviation
was 1.0 point higher than the one used for sample
size calculation. From these figures 305 assessable
patients should have been included in each group,
much more than the planned number.
Therefore, based on EMEA ‘Point to consider’
(CPMP/EWP/492/99), an amendment was proposed
and accepted by the Ethics Committee to switch
from superiority to non-inferiority. The non-infer-
iority was accepted if the difference between Qvar
and comparator with the poorest result on the
Juniper score change did not exceed 0.5 (upper
confidence interval limit). If 0 was not included in
the confidence interval, a statistically significant
difference was set out.
The comparability of treatment groups at base-
line was assessed using a one-factor ANOVA for
quantitative variables, the w2-test for non-ordinal
or 2-class qualitative variables (or Fisher’s exact
test if appropriate), or the Wilcoxon signed rank
test for ordinal variables with more than 2 classes.
Standard deviation was calculated from a 2-way
ANOVA including the three treatment groups and
baseline value as covariable. The 95% confidence
intervals (95%CI) of the difference between Qvar
Autohaler and each comparator were calculated
from the above-mentioned model. It was concluded
that the non-inferiority of Qvar Autohaler if the
upper limit of the 95%CI of the difference between
Qvar Autohaler and the comparator with the
poorest outcome was not greater than 0.5.
Secondary criteria were analyzed in the ITT Set
using a 2-way ANOVA (treatment and center).
Comparisons of treatments with each other were
performed following the Bonferroni method.
Descriptive statistics were performed for general
adverse events and qualitative local safety vari-
ables.
All analyses were performed using the SAS soft-
ware, release 8.1 (SAS Institute, Cary, NC, USA).Results
Baseline patient characteristics
The following populations have been analyzed: the
Safety Set (n ¼ 460) included all randomized
patients who received at least one dose of study
treatment; the intent-to-treat (ITT) Set (n ¼ 446)
included all randomized patients who received at
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one assessment for the main endpoint under
treatment; and the Per Protocol (PP) Set
(n ¼ 353) included all patients eligible for the ITT
Set after exclusion of those presenting with major
protocol violations.
Baseline patient characteristics (safety set) are
summarized in Table 1. Values were much similar
and no relevant difference was noted between
groups regarding age, sex-ratio, duration of asthma
and ongoing allergies. In accordance with the
stratification process, about two-thirds of the
patients were treated with LAb2 (64%, 64% and
65%, respectively, in the Qvar Autohaler, budeso-
nide and fluticasone groups). Among patients
treated with LAb2, 46% were treated with for-
moterol and 42% with salmeterol without differ-
ence of the repartition between groups. Mean
values for baseline vital signs were almost identical
in the three treatment groups. Oro-pharyngeal
examination was normal for all patients (no oral
candidiasis, dysphonia or hoarse voice signs were
present).Table 1 Baseline patient characteristics (safety set).
Parameter Qva
Aut
ðn ¼
Age (years) M7SD 42.
Range 19–
Sex Male n (%) 81
Duration of asthma (years) M7SD 17.
Range 0–5
Ongoing allergies % 58
Mean ICS daily dosage (equivalent
beclomethasone) mg/d
M7SD
Patients treated with LAb2 n (%) 95
Formoterol n (%) 43/
Salmeterol n (%) 41/
Baseline Juniper score M7SD 2.0
Range 0–4
FEV1 (% of predicted value) M7SD 76.
Range 27–
SVC (% of predicted value) M7SD 88.
Range 44–
FEV1/SVC (%) M7SD 69.
Range 38–
FEF25–75 (% of predicted value) M7SD 54.
Range 11–
RV (% of predicted value) M7SD 143
Range 34–
FRC (% of predicted value) M7SD 117
Range 36–
TLC (% of predicted value) M7SD 105
Range 71–The baseline Juniper score was almost identical
in the three treatment groups (2.071.0 in the Qvar
Autohaler group, versus 1.970.9 and 2.070.9,
respectively, in the budesonide and fluticasone
groups) and no relevant difference was shown as
well for baseline PFT parameters.
Study withdrawals were 7,4% 13,6% and 5,4% in
Qvar Autohaler budesonide and fluticasone groups,
respectively.Efficacy results
Asthma Control Questionnaire
Descriptive statistics of the main efficacy endpoint
(change between baseline and last assessment
under treatment for the Juniper questionnaire
score) are given in Table 2. The mean change from
baseline was similar in the three treatment groups
(1.071.0 in the Qvar Autohaler group, versus
0.870.9 and 0.871.0, respectively, in the
budesonide and fluticasone groups) with no sig-
nificant treatment effect. The 95% confidencer
ohaler
Budesonide
Turbuhaler
Fluticasone
Diskus
P
149Þ ðn ¼ 162Þ ðn ¼ 149Þ
4714.1 42.9713.8 42.1713.5 NS
75 18–77 18–85
(54) 75 (46) 74 (50) NS
6 713.6 17.1714.0 15.8711.9 NS
9 0–57 0–52
60 58 NS
4467309 3827255 NS
(64) 104(64) 97 (65) NS
95 (45) 50/104 (48) 44/97(45)
95 (43) 41/104 (39) 41/97(42)
71.0 1.970.9 2.070.9 NS
.7 0.3–4.4 0.1–4.4
6718.5 79.3718.0 76.7716.8 NS
120 27–132 39–112
8716.1 91.2716.7 89.8724.4 NS
124 45–139 18–300
5712.8 70.2712.9 71.2715.0 NS
109 40–106 38–148
0723.1 57.6724.6 55.4721.8 NS
125 10–143 8–122
.2755.0 137.9757.8 145.0757.9 NS
345 1–383 24–371
.8733.8 117.5739.0 118.1735.1 NS
236 33–348 23–278
.0718.4 105.7719.2 109.2747.1 NS
181 68–198 51–609
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Table 2 Evolution of the Juniper score from baseline.
Change of the Juniper score between baseline and last
value under treatment
Qvar
Autohaler
Budesonide
Turbuhaler
Fluticasone
Diskus
ITT set N 145 153 148
M7SD 1.071.0 0.870.9 0.871.0
Range 3.9 to 2.7 3.9 to 1.6 4.4 to 1.6
95% Confidence interval of the
difference between Qvar autohaler
and comparators
[0.30; 0.07] [0.29; 0.08]
Patients treated with LAb2 N 92 98 96
M7SD 1.0 71.0 0.970.9 0.670.9
Range 3.9 to 2.1 2.7 to 1.4 3.3 to 1.6
95% Confidence interval of the
difference between Qvar autohaler
and other treatment groups
[0.34; 0.15] [0.53; 0.05]*
Patients not treated with LAb2 N 53 55 52
M7SD 1.071.1 0.871.1 1.271.0
Range 3.4 to 2.7 3.9 to 1.6 4.4 to 0.4
95% Confidence interval of the
difference between Qvar autohaler
and other treatment groups
[0.44; 0.18] [0.14; 0.48]
*Statistically significant superiority of Qvar autohaler compared to fluticasone.
M. Molimard et al.774intervals of the difference were [0.30; 0.07]
between Qvar Autohaler and fluticasone, and
[0.29; 0.08] between Qvar Autohaler and bude-
sonide, thus showing the non-inferiority of Qvar
Autohaler compared to the other treatments. The
analysis performed in the PP Set gave similar
results.
For patients treated with LAb2, the change from
baseline was higher in the Qvar Autohaler group
(1.071.0, versus 0.970.9 and 0.670.9,
respectively, in the budesonide and fluticasone
groups). The 95% confidence intervals showed the
non-inferiority of Qvar Autohaler compared to
budesonide [0.34;0.15], and demonstrated a
statistically significant superiority of Qvar Auto-
haler compared to fluticasone [0.53;0.05]. The
analysis performed in the population of patients
who were not receiving LAb2 showed non-inferior-
ity of Qvar Autohaler compared to both compara-
tors (Table 1).
Results of the by-item analysis for the individual
clinical criteria of the Juniper score are illustrated
in Fig. 1. For the item nocturnal awakening, the
mean change from baseline was higher in the Qvar
Autohaler group (1.071.4), versus 0.771.3 in
the budesonide group and 0.871.4 in the
fluticasone group. The 95% confidence intervals
showed the non-inferiority of Qvar Autohaler
compared to fluticasone [0.30; 0.08], and alsodemonstrated a statistically significant superiority
of Qvar Autohaler compared to budesonide [0.43;
0.05]. The analysis for other items of the Juniper
questionnaire showed the non-inferiority, but no
superiority of Qvar Autohaler compared to budeso-
nide and fluticasone.Evolution of PFT parameters
The evolution of PFT parameters from baseline
in the ITT Set is presented in Table 3 for all
patients and in Table 4 for patients treated
with long-acting b-agonist. Similar results
were obtained in the three treatment groups,
and no statistically significant differences
between Qvar Autohaler and comparators were
found.Compliance
Descriptive statistics indicate that treatment
compliance was similar in the budesonide and
fluticasone groups (81729% and 80718%, respec-
tively) and higher compared to the Qvar Autohaler
group (68725%). Due to the differences in com-
pliance assessment between groups (weighing
vs. counting), no statistical comparison was
performed.
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Figure 1 Decrease between baseline and last assessment under treatment for the clinical items of the Juniper asthma
control questionnaire.
Table 3 Evolution of pulmonary function test parameters (ITT set).
Mean change between baseline and last
value under treatment
Qvar
Autohaler
Budesonide
Turbuhaler
Fluticasone
Diskus
P
ðn ¼ 145Þ ðn ¼ 153Þ ðn ¼ 148Þ
FEV1 (ml) 2207430 2107440 2807490 0.250
SVC (ml) 1407470 1107470 2107680 0.071
FEV1/SVC (%) 3.2711.3 3.6710.0 3.2711.1 0.967
FEF 25–75 (ml/s) 3307850 2707760 4107820 0.243
RV (ml) 30071020 17071040 26071090 0.388
FRC (ml) 13071050 807840 1807980 0.354
TLC (ml) 9071090 5071020 11071150 0.703
*Comparisons of treatments with each other not significant (Bonferroni method).
Table 4 Evolution of pulmonary function test parameters (patients treated with LAb2).
Mean change between baseline and last
value under treatment
Qvar
Autohaler
ðn ¼ 92Þ
Budesonide
Turbuhaler
ðn ¼ 98Þ
Fluticasone
Diskus
ðn ¼ 96Þ
P
FEV1 (ml) 2507470 2507470 2107510 0.690
VC (ml) 1307500 607500 1907730 0.411
FEV1/SVC (%) 3.8711.8 5.1710.8 2.5711.9 0.451
FEF 25–75 (ml/s) 4007760 3207810 3007810 0.713
RV (ml) 44071150 9071100 22071110 0.189
FRC (ml) 18071180 107860 14071030 0.405
TLC (ml) 20071240 3071120 3071150 0.627
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Local safety
The incidence of oral candidiasis was low, remain-
ing lower or equal to 3.5% at any visit in the three
treatment groups. Erythema, discomfort and pain,
whenever present, were most often rated as
intermediate or moderate.
Overall 31 patients (7.1%) presented with signs of
hoarse voice at Visit 2, compared with 45 (10.5%) at
Visit 3 and 36 (8.6%) at Visit 4. The incidence of
signs of dysphonia was lower in the Qvar Autohaler
group; however, no significant difference was
shown between the three groups.
Overall 27 patients (6.2%) presented with signs
of dysphonia at Visit 2, compared with 35 (8.2%)
at Visit 3 and 28 (6.7%) at Visit 4. No signi-
ficant difference was shown between the three
groups.
Only 5 patients overall (1.1%) presented with
cough within 15min after inhalation at Visit 2 and
Visit 3 and 4 patients at Visit 4 (0.95%).General safety
Overall 38.3% (57/149) of Qvar Autohaler patients
suffered at least one adverse event of any kind
compared with 34.6% (56/162) of budesonide
patients and 36.9% (55/149) of fluticasone patients.
This difference was not statistically significant
(P ¼ 0:791). Central and peripheral nervous system
disorders were the most common (mainly dyspho-
nia), being reported by 18.1% of Qvar Autohaler
patients, 18.5% of budesonide patients and 20.1% of
fluticasone patients (the discrepancy with the local
safety results is linked to the differences in
assessment of safety data by the physician and
the patient). They were followed by respiratory
system disorders that were reported by 18.8% of
Qvar Autohaler patients, 14.2% of budesonide
patients and 16.1% of fluticasone patients and
moniliasis (2.7%, 2.5% and 4.0% of patients,
respectively). The proportion of patients experien-
cing events which were thought by the investigator
to be possibly or probably related to study treat-
ment were similar, with 18.8% of patients in the
Qvar Autohaler group, 19.1% in the budesonide
group and 22.8% in the fluticasone group
(P ¼ 0:628). The most frequently related adverse
event was dysphonia in the three treatment groups
(13.4%, 16.0% and 19.5% of patients, respectively,
in the Qvar Autohaler, budesonide and fluticasone
groups), that led to treatment withdrawal for one
patient in each of the Qvar Autohaler and budeso-
nide groups and for 2 patients in the fluticasone
group.Discussion
This randomized, controlled, open label study
involved 460 patients recruited in 69 centers, to
compare the efficacy of Qvar Autohaler with
Fluticasone Diskus and Budesonide Turbuhaler, in
the treatment of poorly controlled moderate to
severe asthma (pragmatic definition) in adult
patients. As the Qvar actuator is distinctly different
from other actuators in shape and color, blinding
the study would have involved the use of several
inhalers instead of one. Outside the rigidly con-
trolled setting of a conventional clinical trial, it
would probably have led to under-use of all inhalers
and a dilution of information gathered in the study.
In addition, such double-dummy designs do not
reflect normal clinical practice.
Treatment allocation was stratified on the con-
comitant treatment with LAb2, following a 2:1 Yes/
No ratio, thus enabling reliable analyses in the
corresponding sub-populations. The study did not
involve any change to the patients’ usual non-
corticoid maintenance treatment that should have
remained unchanged during the last 30 days before
inclusion and throughout the study. Study treat-
ments were administered at equipotent dosages
(800 mg/day for Qvar Autohaler, 1000 mg/day for
Fluticasone Diskus and 1600 mg/day for Budesonide
Turbuhaler) for a 12-week duration, enabling a
reliable evaluation of the improvement of asthma
control, as assessed by the evolution of the score
for the E. Juniper Asthma Control Questionnaire
between baseline and the end of study.
No significant differences were observed be-
tween groups for demographic parameters. In
addition, for patients who were receiving LAb2,
the repartition of salmeterol and formoterol was
similar in the three treatment groups, so that any
difference in this sub-population cannot be related
to a bias linked to the LAb2 molecule.
The analysis of the main criterion showed the
non-inferiority of Qvar Autohaler compared to
fluticasone and budesonide.
The statistically significant superiority of Qvar
Autohaler over fluticasone that was observed for
the main criterion in patients receiving LAb2 was
rather unexpected. Indeed, fluticasone is a potent
anti-inflammatory drug and the bronchodilation
effect of LAb2 could have masked clinical expres-
sion of persistent inflammation.18 It may be linked
to a specific activity of Qvar Autohaler on small
airways and/or a better acceptability or use of the
delivery system. Indeed, the extra fine aerosol of
Qvar Autohaler allows achieving a more homoge-
neous deposition throughout the lungs.4 Flutica-
sone Diskus with a larger MMAD has a smaller and
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Moreover, Diskus being a dry powder inhaler the
airstream created during inspiration is essential in
aerosolizing the particles and therefore, the
quality of deposition varies with the inspiratory
flow, which influences the delivered dose and the
fine respirable mass.20 On the other hand, as an
MDI, Qvar Autohaler allows the delivery of a more
consistent dose, independent of inspiratory flow.21
These results suggest that despite the broncho-
dilation with the LAb2, optimizing the anti-inflam-
matory treatment is necessary especially for the
more severe patients.
The by-item analysis of the Juniper questionnaire
in the overall population showed a statistically
significant superiority of Qvar Autohaler over
budesonide for the item nocturnal awakening.
Once again, the lung deposition of budesonide
Turbuhaler is smaller compared to Qvar Autohaler,
not exceeding 32%, and decreases when inspiratory
flow does not reach 60 l/min.22
Exacerbation rate and oral seroid intake are
important features of asthma control but because
of the short duration of the study they were not
monitored. However, study withdrawal and respira-
tory adverse event are markers of exacerbation.
They were few and similar in all groups.
No significant difference was shown between
groups for PFT parameters. However, the more
important decrease in residual volume observed
under Qvar Autohaler (440ml) compared with
budesonide (90ml) and fluticasone (220ml)
showing decreased air trapping could reflect
peripheral anti-inflammatory efficacy of Qvar Auto-
haler.
Overall this study demonstrated the non-infer-
iority of Qvar Autohaler 800 mg/d compared to
fluticasone Diskus 1000 mg/d and budesonide Tur-
buhaler 1600 mg/d for the improvement of asthma
control in adult patients presenting with moderate
to severe asthma, and also showed that increasing
the dosage of corticoids may be valuable when
symptoms make it necessary. In addition for
patients treated with LAb2 a better asthma
control was achieved with Qvar Autohaler com-
pared to fluticasone Diskus suggesting that target-
ing the whole lung including small airways with the
extra fine aerosol of beclomethasone may be
beneficial.Acknowledgments
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